Bristol-Myers Squibb Co. (BMY): Consensus Target

Bristol-Myers Squibb (BMY) is developing synergy with biotech laboratories by acquiring immunology startups. The steady cash flow from oncology drugs is maintained at 64.82, although the risk of losing exclusive rights forces the company to allocate resources toward new developments. This price chart visualizes the current trend. Finding a market bottom and updating the asset portfolio will serve as the foundation for future profit growth.

BMY Bristol-Myers Squibb Co. Price Target Chart (07/04/2022 - 11/14/2026)

Analytical breakdowns for BMS (BMY)

- current price and projected stock value:

Price Chart bms.com|BMY - Price Target Chart

- stock exchange capitalization data:

Market Valuation BMS|BMY - Real Price to Acquire Entire Company

- book value of equity indicators:

Net Asset Value per Share Bristol Myers Squibb|BMY - Company Book Value|Market Capitalization to Net Assets bms.com|BMY - Company Total Assets

- business debt structure and liquidity details:

- earnings and multiples data:

BMY - Net Income|Expected Net Income Bristol-Myers Squibb|BMY - P/E Multiple|Future Price to Earnings Multiple Bristol Myers Squibb Company|BMY - Price/Earnings to Growth Ratio|Company Value to EBITDA BMS|BMY - Profit before payment of interest, taxes and amortization|Earnings per share for the last twelve months Bristol Myers Squibb|BMY - Net earnings per share (EPS TTM)|Year-over-year earnings per share growth for the last 12 months bms.com|BMY - Earnings growth in current year|Consensus forecast of earnings per share growth for next year Bristol-Myers Squibb

- total revenue and sales volume data:

BMY - Company Revenue|Company Revenue Forecast bms.com|BMY - P/S Multiple|Projected Price to Revenue BMS

Fundamental company analysis:bms.com, BMY

This indicator represents the weighted average of target prices from leading analysts, reflecting the aggregate market valuation of the business's fair value. The trend in expert price targets allows for an assessment of Bristol-Myers Squibb (BMY) resilience in the face of patent risks and the effectiveness of R&D investments in countering the expansion of generic manufacturers within the highly competitive pharmaceutical sector.

Competitors of Bristol-Myers Squibb